open access

Vol 44, No 2 (2012 Apr-Jun)
Original and clinical articles
Published online: 2012-08-08
Submitted: 2012-08-08
Accepted: 2012-08-08
Get Citation

The influence of low flow anaesthesia on renal function in cancer patients previously treated with nephrotoxic chemotherapeutic agents

Maria Wujtewicz, Wioletta Sawicka, Wojciech Wenski, Andrzej Marciniak, Magdalena A. Wujtewicz, Piotr Stepnowski, Paweł Twardowski, Anna Dylczyk-Sommer, Radosław Owczuk
Anaesthesiol Intensive Ther 2012;44(2):71-75.

open access

Vol 44, No 2 (2012 Apr-Jun)
Original and clinical articles
Published online: 2012-08-08
Submitted: 2012-08-08
Accepted: 2012-08-08

Abstract

BACKGROUND: The aim of this study was to assess renal morbidity, associated with the use of low flow anaesthesia (LFA), in cancer patients previously treated with nephrotoxic chemotherapeutic agents.

METHODS: Seventy-five patients, aged 30–70 years, scheduled for elective surgery, were randomly allocated to three groups: Group A included those patients who had received nephrotoxic chemotherapeutic agents (cisplatin, carboplatin, methotrexate or cyclophosphamide) within 90 days before surgery, and who were anaesthetised with low flow (0.8–1 L min–1) air-oxygen-sevoflurane (1–3 MAC) anaesthesia; Group B included similar patients who received high flow (6 L min–1) anaesthesia. Non-cancer patients receiving low flow anaesthesia served as controls. Blood was sampled for serum creatinine, BUN, cistatin C, and electrolytes (Na+, K+, Cl–, Ca2+, P3+, Mg2+) before anaesthesia, and one, three and five days after.

RESULTS: There were no statistically significant differences between the groups. Conclusions. The use of low flow sevoflurane anaesthesia is not associated with an increased risk of nephrotoxicity in those previously exposed to nephrotoxic chemotherapeutic agents.

Abstract

BACKGROUND: The aim of this study was to assess renal morbidity, associated with the use of low flow anaesthesia (LFA), in cancer patients previously treated with nephrotoxic chemotherapeutic agents.

METHODS: Seventy-five patients, aged 30–70 years, scheduled for elective surgery, were randomly allocated to three groups: Group A included those patients who had received nephrotoxic chemotherapeutic agents (cisplatin, carboplatin, methotrexate or cyclophosphamide) within 90 days before surgery, and who were anaesthetised with low flow (0.8–1 L min–1) air-oxygen-sevoflurane (1–3 MAC) anaesthesia; Group B included similar patients who received high flow (6 L min–1) anaesthesia. Non-cancer patients receiving low flow anaesthesia served as controls. Blood was sampled for serum creatinine, BUN, cistatin C, and electrolytes (Na+, K+, Cl–, Ca2+, P3+, Mg2+) before anaesthesia, and one, three and five days after.

RESULTS: There were no statistically significant differences between the groups. Conclusions. The use of low flow sevoflurane anaesthesia is not associated with an increased risk of nephrotoxicity in those previously exposed to nephrotoxic chemotherapeutic agents.

Get Citation

Keywords

anaesthesia, methods, low flow; anaesthetics, volatile, sevoflurane; chemotherapy, complications, nephrotoxicity

About this article
Title

The influence of low flow anaesthesia on renal function in cancer patients previously treated with nephrotoxic chemotherapeutic agents

Journal

Anaesthesiology Intensive Therapy

Issue

Vol 44, No 2 (2012 Apr-Jun)

Pages

71-75

Published online

2012-08-08

Bibliographic record

Anaesthesiol Intensive Ther 2012;44(2):71-75.

Keywords

anaesthesia
methods
low flow
anaesthetics
volatile
sevoflurane
chemotherapy
complications
nephrotoxicity

Authors

Maria Wujtewicz
Wioletta Sawicka
Wojciech Wenski
Andrzej Marciniak
Magdalena A. Wujtewicz
Piotr Stepnowski
Paweł Twardowski
Anna Dylczyk-Sommer
Radosław Owczuk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Świętokrzyska 73 St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl